Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant698 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06064500 | Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer | approved for marketing | — | — | AmgenINDUSTRY | 4 | Mar 10, 2025 | clinicaltrials |
| NCT03906331 | Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 13 | Jan 17, 2025 | clinicaltrials |
| NCT04204928 | Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC | approved for marketing | — | — | Blueprint Medicines CorporationINDUSTRY | 0 | Aug 13, 2021 | clinicaltrials |
| NCT04504513 | Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer | approved for marketing | — | — | G1 Therapeutics, Inc.INDUSTRY | 0 | Mar 19, 2021 | clinicaltrials |
| NCT04334837 | Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs) | approved for marketing | — | — | Curium US LLCINDUSTRY | 0 | Oct 9, 2020 | clinicaltrials |
| NCT04291937 | A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA | approved for marketing | — | — | Jazz PharmaceuticalsINDUSTRY | 0 | Jun 19, 2020 | clinicaltrials |
| NCT01377532 | Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma | approved for marketing | — | — | University of California, San FranciscoOTHER | 1 | May 6, 2020 | clinicaltrials |
| NCT03089658 | Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC) | approved for marketing | — | — | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 9, 2019 | clinicaltrials |
| NCT02961491 | Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma | approved for marketing | — | — | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 30, 2019 | clinicaltrials |
| NCT02705313 | EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx | approved for marketing | — | — | Advanced Accelerator ApplicationsINDUSTRY | 1 | Apr 9, 2018 | clinicaltrials |
| NCT01683110 | Expanded Access of Cabozantinib in Medullary Thyroid Cancer | approved for marketing | — | — | ExelixisINDUSTRY | 1 | Jan 16, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Mar 10, 2025source: clinicaltrials